Analyzing Zoetis (NYSE:ZTS) & ANI Pharmaceuticals (NASDAQ:ANIP)

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) and Zoetis (NYSE:ZTS – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, analyst recommendations, profitability, institutional ownership and earnings.

Valuation and Earnings

This table compares ANI Pharmaceuticals and Zoetis”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ANI Pharmaceuticals $883.37 million 1.84 $78.34 million $5.02 14.23
Zoetis $9.47 billion 3.59 $2.67 billion $5.88 14.23

Zoetis has higher revenue and earnings than ANI Pharmaceuticals. Zoetis is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

ANI Pharmaceuticals has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500.

Profitability

This table compares ANI Pharmaceuticals and Zoetis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ANI Pharmaceuticals 11.22% 28.34% 11.18%
Zoetis 26.15% 85.90% 18.39%

Analyst Ratings

This is a breakdown of current recommendations and price targets for ANI Pharmaceuticals and Zoetis, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ANI Pharmaceuticals 0 4 3 0 2.43
Zoetis 1 12 8 0 2.33

ANI Pharmaceuticals presently has a consensus target price of $100.00, indicating a potential upside of 39.98%. Zoetis has a consensus target price of $101.25, indicating a potential upside of 21.04%. Given ANI Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts plainly believe ANI Pharmaceuticals is more favorable than Zoetis.

Institutional & Insider Ownership

76.0% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 92.8% of Zoetis shares are held by institutional investors. 8.1% of ANI Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of Zoetis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Zoetis beats ANI Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

About ANI Pharmaceuticals

(Get Free Report)

ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. Its portfolio includes products in areas such as rare disease, specialty care and established brands, alongside a range of generic drugs. The company’s rare-disease portfolio includes Purified Cortrophin Gel, a prescription medicine used to treat certain inflammatory and other conditions. ANI also produces and markets complex and specialty generics, which can require more involved development or manufacturing than conventional generic drugs.

About Zoetis

(Get Free Report)

Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.